1
Brain Tumor 2017
Brain Tumor Meeting 2017
May 18 - 19, 2017Campus Berlin-Buch
Max Delbrck Communications Center (MDC.C)Robert-Rssle-Str. 10
D-13125 Berlin, Germany
Program and Abstracts(Plenaries, Orals and Posters)
This meeting is an activity of
Brain Tumor 2017
2
Campus Berlin-Buch
C31.1- MDHC31 - MDH - Max-Delbrck-HausC84 - Hermann-von-Helmholtz-HausC83 - MDC.CC81 - FMPC71 - Tier- und LaborgebudeD85 - Arnold-Graffi-HausD82 - Karl-Lohmann-HausD80 - Otto-Warburg-HausD79 - Erwin-Negelein-HausD72 - Haus 72D23 - Eckert & Ziegler AGD16 - Bebig GmbH
A9 - PfrtnerA8 - TorhausA15 - Charles River Deutschland GmbHA14 - MensaA13 - Infocenter, Glsernes LaborA10 - BibliothekB64 - epo GmbHB63 - TierhausB61 - Salvadore-Luria-HausB55 - OCVH - Oskar-und-Ccile-Vogt-HausB54 - Hans-Gummel-GstehausB46 - Robert-Rssle-KlinikC27 - Walter-Friedrich-HausC87 - Timofeff-Ressovsky-Haus
3
Brain Tumor 2017
Table of Contents
Acknowledgement 4
Scientific Program 5
List of Plenary Lectures 7
Abstracts of Plenary Lectures 8
List of Oral Presentations selected from Abstracts 10
Abstracts of Oral Presentations 11
List of Poster Presentations 15
Abstracts of Poster Presentations 25
Address List 57
Scientific Committee
Christoph Harms(Charit - Universittsmedizin Berlin, Centrum fr Schlaganfallforschung Berlin)
Frank Heppner(Charit - Universittsmedizin Berlin, Institut fr Neuropathologie)
Helmut Kettenmann (Max-Delbrck-Centrum fr Molekulare Medizin, Zellulre Neurowissenschaften, Chair)
Jrgen Kiwit (Helios Klinikum Buch, Klinik fr Neurochirurgie)
Michael Synowitz(Universittsklinikum Schleswig-Holstein, Klinik fr Neurochirurgie, Co-chair)
Peter Vajkoczy(Charit - Campus Virchow-Klinikum, Klinik und Poliklinik fr Neurochirurgie)
Susanne Wolf(Max-Delbrck-Centrum fr Molekulare Medizin, Zellulre Neurowissenschaften)
Brain Tumor 2017
4
Acknowledgement
Cyagen Biosciences GmbH, Neu-Isenburg
Deutsche Forschungsgemeinschaft Bonn
3di GmbH, Jena
Einstein Center for Neuroscience Berlin
Helios Kliniken, Berlin-Buch
Max Delbrck Center for Molecular Medicine (MDC) in der
Helmholtz-Gemeinschaft, Berlin - Buch
NeuroCure Cluster of Excellence, Berlin
World Precision Instruments, Berlin
We gratefully acknowledge the financial support of the following partners:
5
Brain Tumor 2017
Scientific Program
Thursday, May 18, 2017
14.00 -14.05 Welcome Address: Helmut Kettenmann
14.05 - 15.25 Session I Chair: Jrgen Kiwit14.05 - 14.45 Plenary Lecture I Eric Charles Holland (Seattle, USA) Gliomas: Big human data and mouse models
14.45 - 15.05 Oral Presentation I Roberto Fiorelli (Phoenix, USA) Molecular and cyto-architectonic reshaping of the human svz during glioma invasion 15.05 - 15.25 Oral Presentation II Dinorah Friedmann-Morvinski (Tel Aviv, Israel) Functional characterization of oncogenic-induced cell pasticity in glioblastoma
15.25 - 16.00 Poster Session and Coffee Break
16.00 - 17.20 Session II Chair: Susanne Wolf16.00 - 16.40 Plenary Lecture II Cameron W. Brennan (New York, USA) Molecularheterogeneityandinstabilityofdiffusegliomas:modelsandclinicalpractice
16.40 - 17.00 Oral Presentation III Ccile Maire (Hamburg, Germany) Optical barcoding: A new technique to analyze tumor heterogeneity
17.00 - 17.20 Oral Presentation IV Paolo Malatesta (Genoa, Italy) Immunoescape during glioma progression
17.20 - 17.50 Poster Session and Coffee Break
17.50 - 19.10 Session III Chair: Peter Vajkoczy17.50 - 18.30 Plenary Lecture III Frank Winkler (Heidelberg, Germany) News from tumor microtubes in gliomas
18.30 - 18.50 Oral Presentation V Pooran Singh Dewari (Edinburgh, UK) AnefficientandscalableCRISPR/Cas9pipelineforepitopetagginginneuralandgliomastemcells
18.50 - 19.10 Oral Presentation VI Roland Klin (Mnchen, Germany) Newlyidentifiedpericyte-progenitorcellspromoteGBM-angiogenesis
19.15 - 20.00 Bus Transfer to the Berlin Museum of Medical History / Charit
20.00 Reception at the Berlin Museum of Medical History / Charit
Brain Tumor 2017
6
Friday, May 19, 2017
9.00 - 10.20 Session IV Chair: Christoph Harms9.00 - 9.40 Plenary Lecture IV Colin Watts (Cambridge, UK) Surgical strategies to interrogate the genomics of glioblastoma
9.40 - 10.00 Oral Presentation VII Hrvoje Miletic (Bergen, Norway) Long-term prodrug administration improves lentiviral vector mediated suicide gene therapy of glioblastoma
10.00 - 10.20 Oral Presentation VIII Julia Neumann (Hamburg, Germany) Activation of shh-and wnt-signaling in neural progenitors drives formation of embryonal tumors withmultilayeredrosettes(ETMR)
10.20 10.50 Poster Session and Coffee Break
10.50 12:10 Session V Chair: David Capper10.50 11.30 Plenary Lecture V Dolores Hambardzumyan (Altanta, USA) Subtypespecificdifferencesinmacrophage/microgliafunctioninglioblastoma
11.30 11.50 Oral Presentation IX Gregor Hutter (Basel, Switzerland) CD47-Sirpa blockade induces a microglial phenotypic shift and promotes active glioblastoma phagocytosis in vivo
11.50 12.10 Oral Presentation X Anna Gieryng (Warszawa, Poland) Minocyclinereducesproductionoftumor-derivedosteopontin/spp1andmodulatestheimmune microenvironment of rat c6 gliomas
12.10 13.10 Lunch (Cafeteria) and Postersession
13.00 15.30 Session VI Chair: Marcus Czabanka13.10 13.50 Plenary Lecture VI Brbara Melndez (Toledo, Spain) Molecular genetics in long-term survivors of glioblastoma
13.50 14.10 Oral Presentation XI Claudio Giachino (Basel, Switzerland) Opposite roles of notch signaling in the formation of distinct glioma subtypes
14.10 14.40 Poster Session and Coffee Break
14.40 15.20 Plenary Lecture VII Richard Gilbertson (Cambridge, UK) Mapping the origins and treatment of brain tumors
15.20 15.30 Awarding of Poster Prizes: Darko Markovic
15.30 Departure
7
Brain Tumor 2017
List of Plenary Lectures
Cameron W. BrennanNeurosurgery Department, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USAMolecularheterogeneityandinstabilityofdiffusegliomas:modelsandclinicalpractice
Richard GilbertsonDepartment of Oncology, Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UKMapping the origins and treatment of brain tumors
Dolores HambardzumyanEmory University School of Medicine, Department of Pediatrics, Atlanta GA 30322, USASubtypespecificdifferencesinmacrophage/microgliafunctioninglioblastoma
Eric Charles HollandUniversity of Washington, Fred Hutchinson Cancer Research Center, Seattle, USAGliomas: Big human data and mouse models
Brbara MelndezMolecular Pathology Research Unit, Virgen de la Salud Hospital, Toledo, SpainMolecular genetics in long-term survivors of glioblastoma
Colin WattsUniversity of Cambridge, John van Geest Centre for Brain Repair, Cambridge , UKSurgical strategies to interrogate the genomics of glioblastoma
Frank WinklerNeurology Clinic and National Center for Tumor Disease University Hospital Heidelberg, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, 69120 Heidelberg, GermanyNews from tumor microtubes in gliomas
Brain Tumor 2017
8
Abstracts of Plenary Lectures
MOLECULAR HETEROGENEITY AND INSTABILITY OF DIFFUSE GLIOMAS: MODELS AND CLINICAL PRACTICECameron BrennanNeurosurgery Department, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USAExtensive genomic and proteomic analyses of diffuse gliomas have revealed a remarkable degree of structure in their mutations and gene expression. For example, signature mutations in genes, including Tert, ATRX, TP53 and chromosomal arms 1p/19q clearly di-stinguish typical astrocytomas and oligodendrogliomas where these entities were previously defined by histopathology. Beyond these signature genes, the constellation of other mutations is also largely constrained to a palette of well-known common events: activating alterations of receptor tyrosine kinases and NF1, and alterations targeting tumor suppressor pathways. This presentation will sum-marize the relationship of common mutations and currently known omic signatures in diffuse gliomas, and investigate some of the mechanisms and ramifications of intratumoral heterogeneity in the responses of glioblastomas to conventional and targeted therapies.
MAPPING THE ORIGINS AND TREATMENT OF BRAIN TUMOURSRichard J. GilbertsonLi Ka Shing Chair of Oncology, Head of Dept. of Oncology, Director, Cambridge Cancer Center, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson Way Cambridge CB2 0RE, UKCancers are distributed unevenly across the body, but the impor-tance of cell intrinsic factors such as stem cell function in determi-ning organ cancer risk is unknown. Over the last 15 years we have developed the technique of cross-species genomics to map cells of origin of brain tumours in the developing nervous system. These studies have revealed that brain tumours arise from matched com-binations of susceptible cell types and oncogenic mutations. More recently we have built on these data to use Cre-recombination of conditional lineage tracing, oncogene, and tumour suppressor alleles to define populations of stem and non-stem cells in multiple mouse organs and test their life-long susceptibility to tumorigene-sis. We show that tumour incidence is determined by the life-long generative capacity of mutated cells. This rel
Top Related